Literature DB >> 10787427

Hepatic lipase deficiency decreases the selective uptake of HDL-cholesteryl esters in vivo.

G Lambert1, M J Amar, P Martin, J Fruchart-Najib, B Föger, R D Shamburek, H B Brewer, S Santamarina-Fojo.   

Abstract

Recent in vitro studies have provided evidence that hepatic lipase (HL) facilitates the selective uptake of HDL cholesteryl esters (CE), but the in vivo physiological relevance of this process has not been demonstrated. To evaluate the role that HL plays in facilitating the selective uptake of HDL-CE in vivo, we studied the metabolism of [(3)H]CEt, (125)I-labeled apolipoprotein (apo) A-I, and (131)I-labeled apoA-II-labeled HDL in HL-deficient mice. Kinetic analysis revealed similar catabolism of (125)I-labeled apoA-I (as well as (131)I-labeled apoA-II) in C57BL controls and HL deficient mice, with fractional catabolic rates (FCR) of 2.17 +/- 0.15 and 2.16 +/- 0.11 d(-)(1) (2.59 +/- 0.14 and 2.67 +/- 0.13 d(-)(1), respectively). In contrast, despite similar hepatic scavenger receptor BI expression, HL-deficient mice had delayed clearance of [(3)H]CEt compared to controls (FCR = 3.66 +/- 0.29 and 4.41 +/- 0.18 d(-)(1), P < 0.05). The hepatic accumulation of [(3)H]CEt in HL-deficient mice (62.3 +/- 2.1% of total) was significantly less than in controls (72.7 +/- 3.0%), while the [(3)H]CEt remaining in the plasma compartment increased (20.7 +/- 1.8% and 12.6 +/- 0.5%) (P < 0.05, all). In summary, HL deficiency does not alter the catabolism of apoA-I and apoA-II but decreases the hepatic uptake and the plasma clearance of HDL-CE. These data establish for the first time an important role for HL in facilitating the selective uptake of HDL-CE in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10787427

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  8 in total

1.  Secretion of hepatic lipase by perfused liver and isolated hepatocytes.

Authors:  X Galan; M Q Robert; M Llobera; I Ramírez
Journal:  Lipids       Date:  2000-09       Impact factor: 1.880

2.  Effects of FXR in foam-cell formation and atherosclerosis development.

Authors:  Grace L Guo; Silvia Santamarina-Fojo; Taro E Akiyama; Marcelo J A Amar; Beverly J Paigen; Bryan Brewer; Frank J Gonzalez
Journal:  Biochim Biophys Acta       Date:  2006-10-14

3.  FoxO transcription factors are required for hepatic HDL cholesterol clearance.

Authors:  Samuel X Lee; Markus Heine; Christian Schlein; Rajasekhar Ramakrishnan; Jing Liu; Gabriella Belnavis; Ido Haimi; Alexander W Fischer; Henry N Ginsberg; Joerg Heeren; Franz Rinninger; Rebecca A Haeusler
Journal:  J Clin Invest       Date:  2018-03-19       Impact factor: 14.808

4.  Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis.

Authors:  G P Hayhurst; Y H Lee; G Lambert; J M Ward; F J Gonzalez
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

Review 5.  Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review.

Authors:  Eva Boes; Stefan Coassin; Barbara Kollerits; Iris M Heid; Florian Kronenberg
Journal:  Exp Gerontol       Date:  2008-11-17       Impact factor: 4.032

6.  Leukocyte-derived hepatic lipase increases HDL and decreases en face aortic atherosclerosis in LDLr-/- mice expressing CETP.

Authors:  Neil J Hime; Audrey S Black; Josh J Bulgrien; Linda K Curtiss
Journal:  J Lipid Res       Date:  2008-07-03       Impact factor: 5.922

Review 7.  Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL.

Authors:  Peiqiu Cao; Haitao Pan; Tiancun Xiao; Ting Zhou; Jiao Guo; Zhengquan Su
Journal:  Int J Mol Sci       Date:  2015-07-28       Impact factor: 5.923

8.  Expression of human hepatic lipase negatively impacts apolipoprotein A-I production in primary hepatocytes from Lipc-null mice.

Authors:  Michelle Bamji-Mirza; Wandong Zhang; Zemin Yao
Journal:  J Biomed Res       Date:  2014-03-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.